BlackRock’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-9,812,928
| Closed | -$191M | – | 5175 |
|
|
2018
Q1 | $191M | Sell |
9,812,928
-24,354
| -0.2% | -$478K | 0.01% | 1401 |
|
|
2017
Q4 | $164M | Sell |
9,837,282
-797,361
| -7% | -$14.6M | 0.01% | 1536 |
|
|
2017
Q3 | $216M | Sell |
10,634,643
-40,419
| -0.4% | -$773K | 0.01% | 1289 |
|
|
2017
Q2 | $172M | Sell |
10,675,062
-141,257
| -1% | -$2.09M | 0.01% | 1421 |
|
|
2017
Q1 | $137M | Buy |
10,816,319
+10,810,343
| +180,896% | +$131M | 0.01% | 1560 |
|
|
2016
Q4 | $79K | Sell |
5,976
-812
| -12% | -$13.9K | ﹤0.01% | 2696 |
|
|
2016
Q3 | $161K | Buy |
6,788
+643
| +10% | +$17.3K | ﹤0.01% | 2307 |
|
|
2016
Q2 | $177K | Buy |
6,145
+1,311
| +27% | +$42.7K | ﹤0.01% | 2174 |
|
|
2016
Q1 | $154K | Buy |
4,834
+2,716
| +128% | +$95.5K | ﹤0.01% | 1809 |
|
|
2015
Q4 | $90K | Buy |
2,118
+459
| +28% | +$18.3K | ﹤0.01% | 1810 |
|
|
2015
Q3 | $59K | Sell |
1,659
-175
| -10% | -$7.88K | ﹤0.01% | 1850 |
|
|
2015
Q2 | $84K | Sell |
1,834
-111
| -6% | -$5.27K | ﹤0.01% | 1846 |
|
|
2015
Q1 | $91K | Hold |
1,945
| – | – | ﹤0.01% | 1799 |
|
|
2014
Q4 | $61K | Hold |
1,945
| – | – | ﹤0.01% | 1871 |
|
|
2014
Q3 | $46K | Hold |
1,945
| – | – | ﹤0.01% | 1947 |
|
|
2014
Q2 | $59K | Sell |
1,945
-111
| -5% | -$2.99K | ﹤0.01% | 1866 |
|
|
2014
Q1 | $54K | Hold |
2,056
| – | – | ﹤0.01% | 1890 |
|
|
2013
Q4 | $52K | Sell |
2,056
-75
| -4% | -$1.67K | ﹤0.01% | 1920 |
|
|
2013
Q3 | $43K | Buy |
2,131
+91
| +4% | +$1.88K | ﹤0.01% | 1900 |
|
|
2013
Q2 | $41K | Buy |
+2,040
| New | +$36.2K | ﹤0.01% | 1944 |
|
BlackRock's IPXL Position: Q2 2018 in Review
BlackRock sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 9,812,928 shares — an estimated $191M sold.
BlackRock first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $216M in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- BlackRock reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- BlackRock sold 9,812,928 Impax Laboratories, Inc. shares in Q2 2018, an estimated $191M.
- BlackRock first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- BlackRock's Impax Laboratories, Inc. position peaked at $216M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on BlackRock's 13F filing for Q2 2018, filed 9 Aug 2018.